Evidence map›Paper›PMID 35891387›Full record

ArticleViruses2022

Sequence-Specific Features of Short Double-Strand, Blunt-End RNAs Have RIG-I- and Type 1 Interferon-Dependent or -Independent Anti-Viral Effects.

Abhilash Kannan, Maarit Suomalainen, Romain Volle, Michael Bauer, Marco Amsler, Hung V Trinh, Stefano Vavassori, Jana Pachlopnik Schmid, Guilherme Vilhena, Alberto Marín-González and 5 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Abhilash KannanDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.
Maarit SuomalainenDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.ORCID 0000-0002-3276-3008
Romain VolleDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.ORCID 0000-0002-4442-4652
Michael BauerDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.ORCID 0000-0002-8156-4603
Marco AmslerDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.
Hung V TrinhDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.
Stefano VavassoriDivision of Immunology, University Children's Hospital Zürich, 8032 Zürich, Switzerland.
Jana Pachlopnik SchmidDivision of Immunology, University Children's Hospital Zürich, 8032 Zürich, Switzerland.ORCID 0000-0002-6653-9047
Guilherme VilhenaDepartamento de Física Teórica de la Materia Condensada, Universidad Autónoma de Madrid, E-28049 Madrid, Spain.ORCID 0000-0001-8338-9119
Alberto Marín-GonzálezDepartment of Macromolecular Structures, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Cantoblanco, E-28049 Madrid, Spain.
Ruben PerezDepartamento de Física Teórica de la Materia Condensada, Universidad Autónoma de Madrid, E-28049 Madrid, Spain.ORCID 0000-0001-5896-541X
Andrea FranceschiniDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.
Christian von MeringDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.ORCID 0000-0001-7734-9102
Silvio HemmiDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.
Urs F GreberDepartment of Molecular Life Sciences, University of Zürich, 8057 Zürich, Switzerland.ORCID 0000-0003-2278-120X
University of Zurich · CHSIB Swiss Institute of Bioinformatics · CHUniversidad Autónoma de Madrid · ESConsejo Superior de Investigaciones Científicas · ESUniversity Children's Hospital Zurich · CH

Funding

Swiss National Science Foundation 31003A_179256 / 1Swiss National Science Foundation 51RT 0_126008
6 · The paper itself

Abstract

Pathogen-associated molecular patterns, including cytoplasmic DNA and double-strand (ds)RNA trigger the induction of interferon (IFN) and antiviral states protecting cells and organisms from pathogens. Here we discovered that the transfection of human airway cell lines or non-transformed fibroblasts with 24mer dsRNA mimicking the cellular micro-RNA (miR)29b-1* gives strong anti-viral effects against human adenovirus type 5 (AdV-C5), influenza A virus X31 (H3N2), and SARS-CoV-2. These anti-viral effects required blunt-end complementary RNA strands and were not elicited by corresponding single-strand RNAs. dsRNA miR-29b-1* but not randomized miR-29b-1* mimics induced IFN-stimulated gene expression, and downregulated cell adhesion and cell cycle genes, as indicated by transcriptomics and IFN-I responsive Mx1-promoter activity assays. The inhibition of AdV-C5 infection with miR-29b-1* mimic depended on the IFN-alpha receptor 2 (IFNAR2) and the RNA-helicase retinoic acid-inducible gene I (RIG-I) but not cytoplasmic RNA sensors MDA5 and ZNFX1 or MyD88/TRIF adaptors. The antiviral effects of miR29b-1* were independent of a central AUAU-motif inducing dsRNA bending, as mimics with disrupted AUAU-motif were anti-viral in normal but not RIG-I knock-out (KO) or IFNAR2-KO cells. The screening of a library of scrambled short dsRNA sequences identified also anti-viral mimics functioning independently of RIG-I and IFNAR2, thus exemplifying the diverse anti-viral mechanisms of short blunt-end dsRNAs.

Indexed as

COVID-19Interferon Type IMicroRNAsAntiviral AgentsDEAD Box Protein 58DEAD-box RNA HelicasesHumansInfluenza A Virus, H3N2 SubtypeRNA, Double-StrandedSARS-CoV-2Antiviral AgentsDEAD Box Protein 58DEAD-box RNA HelicasesInterferon Type IMicroRNAsRNA, Double-Strandedadenovirusantiviral agentsDNA virusinfluenza virusinterferonRIG-IRNA therapyRNA virusSARS-CoV-2short double-strand blunt-end RNA

Identifiers

PMID35891387
PMCPMC9322957
OpenAlexW4283703849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.